Penumbra, Inc. (NYSE:PEN) Shares Sold by E. Ohman J or Asset Management AB

E. Ohman J or Asset Management AB lessened its holdings in shares of Penumbra, Inc. (NYSE:PEN - Free Report) by 22.1% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 16,612 shares of the company's stock after selling 4,700 shares during the quarter. E. Ohman J or Asset Management AB's holdings in Penumbra were worth $4,442,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Barclays PLC grew its stake in shares of Penumbra by 16.5% in the 3rd quarter. Barclays PLC now owns 18,025 shares of the company's stock worth $3,502,000 after acquiring an additional 2,559 shares in the last quarter. Trust Point Inc. bought a new stake in shares of Penumbra in the 4th quarter worth $215,000. Mather Group LLC. grew its stake in shares of Penumbra by 208.0% in the 4th quarter. Mather Group LLC. now owns 308 shares of the company's stock worth $73,000 after acquiring an additional 208 shares in the last quarter. WCM Investment Management LLC bought a new stake in shares of Penumbra in the 4th quarter worth $13,451,000. Finally, 17 Capital Partners LLC bought a new stake in shares of Penumbra in the 4th quarter worth $229,000. Institutional investors own 88.88% of the company's stock.

Penumbra Stock Down 0.9%

Shares of PEN traded down $2.29 during midday trading on Monday, reaching $256.61. 560,317 shares of the stock were exchanged, compared to its average volume of 449,014. Penumbra, Inc. has a 52 week low of $148.00 and a 52 week high of $310.00. The company has a current ratio of 6.01, a quick ratio of 3.25 and a debt-to-equity ratio of 0.02. The company's 50 day moving average is $276.89 and its two-hundred day moving average is $267.10. The company has a market capitalization of $9.94 billion, a P/E ratio of 754.74, a PEG ratio of 2.83 and a beta of 0.49.

Penumbra (NYSE:PEN - Get Free Report) last released its earnings results on Wednesday, April 23rd. The company reported $0.83 EPS for the quarter, topping analysts' consensus estimates of $0.66 by $0.17. The firm had revenue of $324.14 million during the quarter, compared to the consensus estimate of $315.72 million. Penumbra had a return on equity of 9.74% and a net margin of 1.17%. The company's revenue was up 16.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.41 earnings per share. On average, sell-side analysts anticipate that Penumbra, Inc. will post 3.67 earnings per share for the current year.

Insider Buying and Selling at Penumbra

In other Penumbra news, EVP Johanna Roberts sold 600 shares of the business's stock in a transaction on Monday, June 2nd. The stock was sold at an average price of $258.17, for a total transaction of $154,902.00. Following the sale, the executive vice president now directly owns 64,714 shares in the company, valued at approximately $16,707,213.38. The trade was a 0.92% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Thomas Wilder sold 360 shares of the business's stock in a transaction dated Monday, March 31st. The shares were sold at an average price of $264.58, for a total transaction of $95,248.80. Following the completion of the transaction, the director now directly owns 4,533 shares of the company's stock, valued at $1,199,341.14. The trade was a 7.36% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 128,845 shares of company stock valued at $36,359,981 in the last quarter. Corporate insiders own 4.20% of the company's stock.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on PEN shares. JPMorgan Chase & Co. boosted their price target on shares of Penumbra from $230.00 to $285.00 and gave the stock an "overweight" rating in a report on Wednesday, February 19th. Needham & Company LLC reissued a "hold" rating on shares of Penumbra in a report on Wednesday, February 19th. Morgan Stanley boosted their price target on shares of Penumbra from $240.00 to $260.00 and gave the stock an "equal weight" rating in a report on Wednesday, February 19th. Wells Fargo & Company boosted their price target on shares of Penumbra from $305.00 to $315.00 and gave the stock an "overweight" rating in a report on Thursday, April 24th. Finally, Piper Sandler reaffirmed an "overweight" rating and set a $330.00 price objective (up from $250.00) on shares of Penumbra in a report on Wednesday, February 19th. Three analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $302.40.

About Penumbra

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.